[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Benha University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":648},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,49,0,25,[9,47,75,99,127,156,187,215,236,258,285,307,331,354,385,415,435,461,488,511,538,559,582,605,628],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100628710","phase-2-intrathecal-bupivacaine-with-or-without-dexmetomidine-for-cesserian-delivery-100628710",false,"NCT07465185","Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery","Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery ;Arandomized Non - Inferiority Study","Inclusion Criteria:\n\n* (1) Full-term pregnant women undergoing elective cesarean section under spinal anesthesia. (2) Age: 20 \\~ 35 years. (3) ASA physical status II \\~ III\n\nExclusion Criteria:\n\n1. Multiple pregnancies.\n2. Cardiovascular disease(e.g., pre-eclampsia and hypertension).\n3. Serious hepatic dysfunction (Child-Pugh class C).\n4. serious renal dysfunction (undergoing dialysis before surgery).\n5. History of alcohol or opioid addiction.\n6. Contraindication to spinal anesthesia.\n7. Refusing to sign informed consent.","FEMALE","20 Years","35 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Cesarean section (CS) is one of the most frequently performed surgical procedures globally, with an increasing demand for safe and effective anesthesia techniques. Regional anesthesia, particularly intrathecal anesthesia, has become the method of choice for elective cesarean deliveries.The most commonly used local anesthetic for intrathecal anesthesia is bupivacaine.Recent studies have focused on adjunctive agents to enhance the efficacy of local anesthetics.",[28],"Anesthesia",[30,31,32,33],"bupivacaine","dexmetomedine","spinal anesthesia","cessarian delivery","RECRUITING","2026-08-15",{"date":37,"type":38},"2026-08-18","ACTUAL",{"date":40,"type":38},"2026-03-15",{"date":42,"type":22},"2026-09-01",{"name":44,"class":45},"Benha University","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100628877","phase-3-anterior-iliopsoas-space-block-versus-peng-block-on-ease-of-positioning-for-spinal-anathesia-in-patients-undergoing-hip-surgeries-100628877","NCT07467356","Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip Surgeries","Impact of Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip Surgeries ;Randomized Clinical Trial","Inclusion Criteria:\n\n* (ASA )classes I and II\n* patients of either sex, above the age of 18 who will undergo hip surgeries( (Dynamic hip screw fixation or hemiarthroplasty)(not older than 2 weeks) with persistent pain and scheduled for surgery under SA with an expected duration of 2.5 hours\n\nExclusion Criteria:\n\n* patient's refusal to participate\n* any contraindications to SA or peripheral nerve blocks\n* history of ischemic heart disease\n* patients on opioids for chronic pain\n* patients with significant cognitive impairment.","ALL","18 Years",{"count":57,"type":22},90,[59],"PHASE3","Total hip arthroplasty (THA) has been one of the most significant advancements in orthopedic surgery over the past century. hip fractures are typically associated with severe pain, effective analgesia is crucial both before and after surgery.Spinal anesthesia (SA) is the most commonly employed method of anesthesia for repairing these fractures.The anterior iliopsoas space block is a considered as a novel technique that targets the lumbosacral trunk as it passes beneath the psoas major muscle, offering potential advantages over the traditional sacral plexus block, which is performed in the supine position.",[62],"Pain Management",[64,65,66,67],"PENG block","anterior iliopsoas space block","ease of positioning","hip surgeries","2026-08-09",{"date":70,"type":38},"2026-08-11",{"date":40,"type":38},{"date":73,"type":22},"2026-09-15",{"name":44,"class":45},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100651682","hybrid-transobturator-tape-versus-conventional-synthetic-tape-for-stress-urinary-incontinence-100651682","NCT07762300","Hybrid Transobturator Tape Versus Conventional Synthetic Tape for Stress Urinary Incontinence","Hybrid Transobturator Tape Versus Conventional Synthetic Tape: A Randomized Controlled Trial Assessing Safety, Efficacy, and Female Sexual Function","Inclusion Criteria:\n\n* Female patients suffering from genuine stress urinary incontinence.\n* Failed conservative management (pelvic floor exercises, medical therapy)\n* Written informed consent.\n\nExclusion Criteria:\n\n* Mixed urinary incontinence with predominant urge component.\n* High-grade pelvic organ prolapse (POP-Q Stage \\>= II), which required surgical intervention.\n* Neurogenic bladder or voiding dysfunction (Post-void residual \\> 100 ml).\n* Coagulopathy or active urinary tract infection.\n* Patients who underwent recent pelvic radiotherapy.\n* Previous incontinence surgery (recurrent cases).",{"count":57,"type":22},[84],"NA","This randomized controlled trial compares the safety, efficacy, and impact on female sexual function of a novel hybrid transobturator tape (combining an autologous rectus fascia strip with a polypropylene mesh) versus standard synthetic transobturator tape in women undergoing surgery for stress urinary incontinence.",[87,88,89,90],"Stress Urinary Incontinence (SUI)","Transobturator Tape","Hybrid Sling","Female Sexual Function","2026-08-08",{"date":93,"type":38},"2026-08-13",{"date":95,"type":38},"2026-07-01",{"date":97,"type":22},"2027-03-01",{"name":44,"class":45},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":46},"100651008","innovative-tube-trabeculectomy-for-advanced-and-refractory-glaucoma-a-randomized-controlled-trial-100651008","NCT07755761","Innovative Tube Trabeculectomy for Advanced and Refractory Glaucoma: A Randomized Controlled Trial","A Prospective, Randomized, Controlled, Single-Center Clinical Trial to Evaluate the Efficacy and Safety of Innovative Tube Trabeculectomy Compared to Conventional Trabeculectomy in Patients With Advanced and Refractory Glaucoma","ITT-RCT","Inclusion Criteria:\n\n\\- • Diagnosis of advanced or refractory primary open-angle glaucoma (POAG) or secondary open-angle glaucoma (excluding neovascular glaucoma).\n\n* Intraocular pressure (IOP) \\> 21 mmHg despite maximal tolerated medical therapy or previous failed glaucoma surgery.\n* Best corrected visual acuity (BCVA) of 20\u002F400 or better.\n* Capable of providing informed consent\n\nExclusion Criteria:\n\n* Previous incisional glaucoma surgery in the study eye (except for prior failed trabeculectomy in the refractory group).\n* Neovascular glaucoma or other forms of secondary glaucoma that may significantly impact wound healing (e.g., uveitic glaucoma).\n* Significant ocular comorbidities that may confound outcome assessment (e.g., severe corneal disease, retinal detachment).\n* Pregnancy or lactation.\n* Participation in another clinical trial within 30 days prior to enrollment.",{"count":108,"type":22},116,[84],"This study aims to compare the efficacy and safety of a novel surgical technique, Innovative Tube Trabeculectomy (ITT), against conventional trabeculectomy in patients with advanced and refractory glaucoma. ITT incorporates a unique preoperative regimen and surgical modifications, including a deep extended scleral tunnel, X-shaped non-absorbable suture, and a nasolacrimal tube implant, designed to enhance aqueous humor outflow and reduce postoperative fibrosis. Participants will be randomized to receive either ITT or conventional trabeculectomy and followed for 12 months to assess intraocular pressure control, medication use, complication rates, and bleb morphology.",[112,113,114],"Glaucoma","Trabeculectomy","Innovative Procedures",[116,117,118],"glaucoma","innovative","tube trabeculectomy","2026-08-05",{"date":121,"type":38},"2026-08-10",{"date":123,"type":38},"2026-08-01",{"date":125,"type":22},"2028-08-01",{"name":44,"class":45},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":134,"minAge":55,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":153,"leadSponsor":155,"locationsCount":46},"100650598","hydrodissection-assisted-bipolar-prostatic-enucleation-versus-conventional-bipolar-enucleation-100650598","NCT07749794","Hydrodissection-Assisted Bipolar Prostatic Enucleation Versus Conventional Bipolar Enucleation","Hydrodissection-Assisted Bipolar Prostatic Enucleation-Enucleoresection With Subcapsular Injection of Diluted Norepinephrine-Methylene Blue Mixture Versus Conventional Bipolar Prostatic Enucleation-Enucleoresection: A Prospective Randomized Comparative Study","Inclusion Criteria:\n\n* Benign prostatic hyperplasia.\n* Prostate volume greater than 60 cc as measured by transrectal ultrasonography.\n* Moderate-to-severe lower urinary tract symptoms, defined as an International Prostate - Symptom Score of 12 or higher.\n* Failure of or poor response to medical management.\n\nExclusion Criteria:\n\n* History of prostate cancer or suspicious findings on prostate biopsy.\n* Active urinary tract infection.\n* Severe cardiovascular, pulmonary, or other systemic comorbidities that contraindicate surgery.\n* Previous prostate surgery, including transurethral resection of the prostate or open prostatectomy.\n* Chronic urinary retention associated with neurogenic bladder. Hypersensitivity to norepinephrine or methylene blue.","MALE",{"count":136,"type":22},100,[84],"This prospective randomized study will compare two surgical techniques for treating benign prostatic hyperplasia. Participants will be assigned to either hydrodissection-assisted bipolar prostatic enucleation-enucleoresection with transrectal ultrasound-guided subcapsular injection of diluted norepinephrine and methylene blue or conventional bipolar prostatic enucleation-enucleoresection without injection.\n\nThe injected mixture is intended to separate the enlarged prostatic tissue from the surgical capsule and reduce bleeding during surgery. The study will evaluate whether the hydrodissection-assisted technique improves operative conditions, surgical outcomes, postoperative recovery, urinary symptoms, and urinary flow compared with the conventional technique.",[140,141],"Prostatic Hyperplasia","Lower Urinary Tract Symptoms",[143,144,145,146,147],"Bipolar prostatic enucleation","Hydrodissection","Subcapsular prostatic injection","Norepinephrine","Methylene blue","NOT_YET_RECRUITING","2026-08-03",{"date":151,"type":38},"2026-08-06",{"date":35,"type":22},{"date":154,"type":22},"2027-08-15",{"name":44,"class":45},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":184,"leadSponsor":186,"locationsCount":46},"100650517","nebulized-glubran-2-assisted-tubeless-pcnl-versus-conventional-pcnl-100650517","NCT07749807","Nebulized Glubran 2-Assisted Tubeless PCNL Versus Conventional PCNL","A Novel Technique in Tubeless Percutaneous Nephrolithotomy Using Nebulized Glubran 2 Versus Conventional Percutaneous Nephrolithotomy: A Prospective Randomized Controlled Study","Inclusion Criteria:\n\n* Age 18 years or older.\n* Single or multiple renal stones measuring 2-3 cm.\n* Renal stones located in an anatomical position suitable for percutaneous nephrolithotomy.\n* Participant considered suitable for PCNL under general anesthesia.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Active urinary tract infection.\n* Renal stones in an anomalous kidney.\n* Uncontrolled hypertension.\n* Uncontrolled diabetes mellitus.\n* Uncorrected coagulopathy.\n* Clinically significant arrhythmia.\n* Distal ureteric obstruction.\n* Fixed hip joints preventing appropriate operative positioning.\n* Previous renal surgery.\n* Requirement for more than one percutaneous puncture.\n* Pelvicalyceal system perforation during the procedure.\n* Excessive intraoperative bleeding.\n* Any intraoperative finding requiring nephrostomy tube placement for safety.",{"count":136,"type":22},[84],"This prospective randomized controlled study will compare two techniques used after percutaneous nephrolithotomy, a procedure for removing kidney stones. Participants with renal stones measuring 2-3 cm will be randomly assigned to either tubeless percutaneous nephrolithotomy with nebulized Glubran 2 used to seal the access tract or conventional percutaneous nephrolithotomy with placement of a nephrostomy tube. The study will evaluate whether the Glubran 2-assisted tubeless technique is safe and effective and whether it can reduce postoperative pain, bleeding, hospital stay, urine leakage, and other complications while maintaining a satisfactory stone-free rate.",[167,168],"Kidney Calculi","Nephrolithiasis",[170,171,172,173,174,175,176,177,178,179,180,181],"Percutaneous nephrolithotomy","Tubeless percutaneous nephrolithotomy","Conventional percutaneous nephrolithotomy","Glubran 2","Cyanoacrylate tissue adhesive","Percutaneous tract sealing","Nephrostomy tube","Kidney stones","Renal calculi","Stone-free rate","Postoperative pain","Postoperative bleeding",{"date":151,"type":38},{"date":42,"type":22},{"date":185,"type":22},"2027-02-01",{"name":44,"class":45},{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":194,"sex":17,"minAge":195,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":199,"phases":4,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":214,"locationsCount":46},"100650464","perineal-ultrasound-post-void-residual-and-lower-limb-alignment-in-stress-incontinence-100650464","NCT07747727","Perineal Ultrasound, Post-Void Residual, and Lower-Limb Alignment in Stress Incontinence","Perineal Ultrasound α\u002Fβ Angles, Post-Void Residual Volume, and Lower-Limb Alignment in Symptomatic and Asymptomatic Postmenopausal Women With Stress Incontinence.","Inclusion Criteria: post menoupausal women, who had at least 12 months of amenorrhea or follicle-stimulating hormone values within the menopausal range and who could stand and walk independently to allow lower-limb and alignment assessments.\n\n\\-\n\nExclusion Criteria:women with urge or mixed incontinence as the dominant symptom, prior pelvic floor or anti-incontinence surgery, severe pelvic organ prolapse (stage 3 or greater), or neurological conditions affecting bladder function or gait, as well as those with hip or spine surgery likely to alter spinopelvic parameters\n\n\\-",true,"50 Years","65 Years",{"count":198,"type":22},120,"OBSERVATIONAL","Stress urinary incontinence (SUI) in postmenopausal women is traditionally considered a local pelvic floor disorder, but emerging evidence suggests that spinopelvic and lower limb alignment may also contribute to continence mechanisms. Transperineal ultrasound α\u002Fβ angles and post void residual (PVR) volume are promising imaging markers that might capture this broader biomechanical phenotype.\n\nObjective To compare hip ultrasound α\u002Fβ angles, PVR volume, and lower limb and spinopelvic alignment between symptomatic and asymptomatic postmenopausal women, and to explore within group correlations between PVR and musculoskeletal alignment variables.",[202],"Stress Urinary Incontinence in Women",[204,205,206,207,208],"Stress Urinary Incontinence","Postmenopause","Ultrasonography","Postvoid Residual Urine","Lower Extremity","2026-07-31",{"date":119,"type":38},{"date":212,"type":38},"2026-02-03",{"date":35,"type":22},{"name":44,"class":45},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":134,"minAge":221,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":46},"100649334","phase-3-intra-prostatic-epinephrine-injection-in-bipolar-transurethral-resection-of-large-prostate-exploring-its-role-in-optimizing-surgical-outcomes-100649334","NCT07733167","Intra-Prostatic Epinephrine Injection in Bipolar Transurethral Resection of Large Prostate: Exploring Its Role in Optimizing Surgical Outcomes","Inclusion Criteria:\n\n* Indication for Prostate Surgery or Procedure - Patients undergoing transurethral resection of the prostate (TURP)\n* Prostate from 80 to 100 gm\n* Failed medical therapy\n\nExclusion Criteria:\n\n* Uncontrolled Hypertension - Patients with significantly high blood pressure despite medication therapy.\n* Unstable angina, recent myocardial infarction, arrhythmias, or severe heart failure.\n* Significant Coagulopathy - Patients with bleeding disorders or on anticoagulants where excessive vasoconstriction may lead to tissue necrosis or inadequate perfusion\n* Hyperthyroidism, Pheochromocytoma or Endocrine Disorders - Patients with catecholamine-secreting tumors or other conditions that can lead to excessive sympathetic stimulation.\n* Treatment in the last 3 months with 5-alpha reductase inhibitors.\n* Genitourinary cancer, urinary tract lithiasis, and urological surgery within the last 3 months","40 Years",{"count":223,"type":22},80,[59],"Intra-Prostatic Epinephrine injection in Bipolar Transurethral resection of large prostate: Exploring Its Role in Optimizing Surgical Outcomes",[227],"Intra-Prostatic Epinephrine Injection in Bipolar Transurethral Resection of Large Prostate","2026-07-28",{"date":230,"type":38},"2026-07-29",{"date":232,"type":38},"2025-03-20",{"date":234,"type":22},"2026-10-20",{"name":44,"class":45},{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":46},"100649398","early-phase-1-comparison-between-the-effect-of-two-different-doses-of-oral-melatonin-on-sleep-quality-after-total-hip-arthroplasty-100649398","NCT07732725","Comparison Between the Effect of Two Different Doses of Oral Melatonin on Sleep Quality After Total Hip Arthroplasty","Comparison Between the Effect of Two Different Doses of Oral Melatonin on Sleep Quality After Total Hip Arthroplasty A Randomized Placebo-Controlled Double-Blind Trial","Inclusion Criteria:\n\n* Elective unilateral total hip arthroplasty.\n\nExclusion Criteria:\n\n* Revision arthroplasty\n* documented sleep disorders requiring treatment,\n* use of other sleep medications preoperatively\n* known melatonin allergy or contraindication.","80 Years",{"count":245,"type":22},150,[247],"EARLY_PHASE1","Considering the fact that melatonin was safely and effectively used in higher doses in multiple surgical conditions , the present study hypothesized that increasing melatonin dose in THA would have better benefits for patients.",[250],"Sleep Disturbance","2026-07-26",{"date":230,"type":38},{"date":254,"type":22},"2026-08-04",{"date":256,"type":22},"2026-11-04",{"name":44,"class":45},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":243,"enrollmentInfo":266,"targetDuration":267,"studyType":199,"phases":4,"briefSummary":268,"conditions":269,"keywords":273,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":282,"leadSponsor":284,"locationsCount":46},"100648597","onsd-trajectory-in-rebound-ich-100648597","NCT07722702","ONSD Trajectory in Rebound ICH","Optic Nerve Sheath Diameter Trajectory During Osmotherapy Weaning as a Predictor of Rebound Intracranial Hypertension in Traumatic Brain Injury","ONSD\u002F INH","Inclusion Criteria:\n\n* Adults (≥18 years) with blunt traumatic brain injury admission GCS ≤12\n* (or GCS 13-15 with CT signs of elevated ICP including midline shift ≥5 mm, effaced cisterns, or significant cerebral edema)\n* clinical decision to initiate 20% mannitol osmotherapy\n\nExclusion Criteria:\n\n* Ocular conditions precluding ONSD measurement (glaucoma, prior ocular surgery,\n* globe or optic nerve trauma,\n* periorbital edema, orbital masses, optic nerve sheath cysts);\n* planned decompressive surgery or evacuation of mass lesion within 48 hours; limitation of life-sustaining therapy; pregnancy; contraindications to mannitol (baseline sodium \\>155 mEq\u002FL, osmolality \\>320 mOsm\u002Fkg, eGFR \\\u003C30 mL\u002Fmin); penetrating TBI; or concurrent spinal cord injury with shock.",{"count":136,"type":22},"6 Weeks","The goal of this prospective observational study is to determine whether the trajectory of optic nerve sheath diameter (ONSD) after osmotherapy weaning can predict rebound intracranial hypertension in adult patients with traumatic brain injury requiring osmotherapy for elevated intracranial pressure. The main questions it aims to answer are:\n\nDoes the trajectory of ONSD during osmotherapy weaning predict the development of rebound intracranial hypertension? What is the diagnostic accuracy of serial ONSD measurements for the early detection of rebound intracranial hypertension? Researchers will compare patients who develop rebound intracranial hypertension with those who do not to determine whether changes in ONSD trajectory differ significantly between the two groups.\n\nParticipants will:\n\nUndergo serial bedside ocular ultrasound examinations for ONSD measurement at predefined time points after osmotherapy weaning.\n\nReceive standard clinical management for traumatic brain injury according to institutional protocols; no additional therapeutic intervention will be administered.\n\nUndergo routine neurological assessments, laboratory investigations, and neuroimaging as clinically indicated.\n\nBe followed for the occurrence of rebound intracranial hypertension and relevant clinical outcomes during their ICU stay",[270,271,272],"Traumatic Brain Injury","Rebound Intracranial Hypertension","Cerebral Edema",[274,275,276,277],"ONSD","Osmotherapy","Rebound ICH","Cerebral edema","2026-07-19",{"date":280,"type":38},"2026-07-23",{"date":42,"type":22},{"date":283,"type":22},"2027-10-01",{"name":44,"class":45},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":196,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":304,"leadSponsor":306,"locationsCount":46},"100647855","first-attempt-insertion-success-of-novel-two-person-lateral-rotation-technique-vs-standard-brain-technique-for-lma-insertion-100647855","NCT07715708","First Attempt Insertion Success of Novel Two Person Lateral Rotation Technique V.S Standard Brain Technique for LMA Insertion","First-Attempt Insertion Success of a Novel Two-Person Lateral Rotation Technique Versus the Standard Brain Technique for Laryngeal Mask Airway Placement: A Randomized Controlled Trial","LMA insertion","Inclusion Criteria:\n\n* Adult patients aged 18-65 years\n* American Society of Anesthesiologists (ASA) physical status I-II\n* Scheduled for elective superficial surgical procedures under general anesthesia (e.g., limb orthopedic surgery, hernioplasty, soft tissue excision)\n* Anticipated surgical duration \\\u003C 90 minutes\n* Body mass index (BMI) 18.5-30 kg\u002Fm²\n\nExclusion Criteria:\n\n* \\- Anticipated difficult airway (Mallampati grade IV, thyromental distance \\\u003C 6 cm, limited neck extension)\n* History of gastroesophageal reflux disease or increased aspiration risk\n* Full stomach or emergency surgery - Intra-abdominal, laparoscopic, head and neck, or prone-position procedures - Known allergy to anesthetic agents\n* Pregnancy\n* Previous pharyngeal or laryngeal surgery - Inability to provide informed consent",{"count":294,"type":22},70,[84],"The goal of this clinical trial is to learn if two person lateral rotation technique of LMA insertion is more successful than the standard technique in achieving effective ventilation on the first introduction of the LMA .The main questions it aims to answer are:\n\nDoes two person lateral rotation technique of LMA insertion lower the number of times needed to inesrt the LMA ?\n\nResearchers will compare two person lateral rotation technique of LMA insertion to standard technique to see if it is more successful\n\nParticipants will be subjected to the two way of LMA insertion",[298,299],"LMA","Ventilation","2026-07-16",{"date":302,"type":38},"2026-07-20",{"date":95,"type":22},{"date":305,"type":22},"2027-01-01",{"name":44,"class":45},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":54,"minAge":314,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":318,"conditions":319,"keywords":321,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":330,"locationsCount":46},"100621801","melatonin-for-post-tonsillectomy-emergence-agitation-in-pediatric-100621801","NCT07375342","Melatonin for Post Tonsillectomy Emergence Agitation in Pediatric","Effect of Preoperative Oral Melatonin on Emergence Agitation Following Pediatric Tonsillectomy: a Randomized Controlled Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status I or II.\n* Parent\u002Flegal guardian provides written informed consent\n\nExclusion Criteria:\n\n* • Known allergy or contraindication to melatonin.\n\n  * Pre-existing neurological or psychiatric disorders (e.g., epilepsy, autism, ADHD).\n  * Children receiving any sedative or psychoactive medication within 48 hours of surgery.\n  * Emergency surgery or any procedure other than tonsillectomy\u002Fadenoidectomy.\n  * Children with known sleep disorders or those taking melatonin supplements.\n  * Developmental delay, neurologic disorders, sleep disorders, or known obstructive sleep apnea requiring ICU postoperatively.\n  * Hepatic or renal dysfunction (ALT\u002FAST \\>2×ULN, Cr \\>1.5 mg\u002FdL)","4 Years","10 Years",{"count":198,"type":22},[84],"The goal of this clinical trial is to learn if melatonin can decrease emergence agitation in pediatric post tonsillectomy. The main questions it aims to answer are:\n\nDoes melatonin decrease emergence agitation in pediatric post tonsillectomy? What medical problems do participants have when taking melatonin? Researchers will compare melatonin to a placebo (a look-alike substance that contains no drug) to see if melatonin works todecrease emergence agitation in pediatric post tonsillectomy\n\nParticipants will receive Oral melatonin at a dose of 0.5 mg\u002Fkg (maximum 20 mg) administered 30 minutes before induction of anesthesia. Dose chosen based on prior pediatric studies and safety data.",[320],"Post Tonsillectomy Emergence Agitation",[322,323,324],"agitation","tonsillectomy","pediatric",{"date":326,"type":38},"2026-07-17",{"date":328,"type":38},"2025-12-10",{"date":123,"type":22},{"name":44,"class":45},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":196,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":341,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":353,"locationsCount":46},"100618308","dexamethasone-dexmedetomidine-and-their-combination-on-post-op-git-function-measured-by-i-ffed-score-post-laparoscopic-cholecystectomy-100618308","NCT07329933","Dexamethasone, Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy","Effect of Dexamethasone, Dexmedetomidine and Their Combination on Postoperative Gastrointestinal Function Measured by I-FEED Score After Elective Laparoscopic Cholecystectomy Surgery: a Randomized Controlled Trial","vomiting","Inclusion Criteria:\n\n* . Age 18-65 years.\n* American Society of Anesthesiologists (ASA) physical status I or II.\n* Scheduled for elective laparoscopic cholecystectomy surgery under general anesthesia.\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or contraindication to any study drug (dexamethasone, dexmedetomidine, or placebo).\n* Pre-existing gastrointestinal motility disorders (e.g., gastroparesis, inflammatory bowel disease).\n* Chronic use of opioids, steroids, or antiemetics.\n* History of severe cardiac disease (e.g., high-grade AV block, severe bradycardia).\n* Uncontrolled diabetes mellitus (HbA1c \\> 8.0%).\n* Emergency surgery or conversion to open surgery.\n* Pregnancy or breastfeeding.\n* Morbid obesity (BMI \\>40).\n* Severe hepatic or renal dysfunction.",{"count":340,"type":22},160,[84],"The goal of this clinical trial is to learn the effect of Dexamethasone and Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy\n\nWhat medical problems do participants have when taking Dexamethasone and Dexmedetomidine? Researchers will compare Dexamethasone and Dexmedetomidine and Their Combination to a placebo (a look-alike substance that contains no drug) to see the effect on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy Participants will receive Dexamethasone 8 mg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.\n\nParticipants will receive Dexmedetomidine 0.5 mcg \u002Fkg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.\n\nParticipants will receive Dexamethasone 8 mg IV + Dexmedetomidine 0.5 mcg\u002Fkg IV+ Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.\n\nParticipants will receive Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia",[344,345,346,347,348],"GIT Function","Cholecystectomy, Laparoscopic","Dexamethasone","Dexmedetomidine","I-FEED Score",{"date":302,"type":38},{"date":351,"type":38},"2025-12-15",{"date":123,"type":22},{"name":44,"class":45},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":361,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":365,"conditions":366,"keywords":372,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":46},"100646805","ovarian-reserve-after-laparoscopic-cystectomy-for-endometriotic-and-non-endometriotic-cysts-100646805","NCT07686783","Ovarian Reserve After Laparoscopic Cystectomy for Endometriotic and Non-Endometriotic Cysts","Ovarian Reserve After Laparoscopic Cystectomy for Endometriotic and Non-Endometriotic Cysts: A Comparative Prospective Cohort Study","Inclusion Criteria:\n\n* Female patients aged 18-45 years\n* Ovarian cyst measuring 6-15 cm in diameter, confirmed by transvaginal ultrasound or MRI\n* Cyst is persistent for more than 3 months if asymptomatic, OR any symptomatic cyst regardless of duration of diagnosis\n* Serum anti-Müllerian hormone (AMH) level ≥ 2 ng\u002FmL, measured within 1 month preoperatively\n* Willingness to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Clinical or ultrasonic suspicion of ovarian malignancy\n* Ovarian cyst associated with pregnancy\n* Previous history of ovarian surgery\n* History of pelvic irradiation or chemotherapy\n* Known endocrine disorders affecting ovarian function (e.g., PCOS, premature ovarian insufficiency, thyroid dysfunction, hyperprolactinemia)\n* Current use of hormonal contraceptives or hormonal therapy within 3 months prior to enrollment\n* Presence of severe systemic disease that contraindicates surgery or general anesthesia\n* Refusal to participate or inability to provide informed consent","45 Years",{"count":363,"type":22},60,[84],"We will conduct this study to estimate the effect of laparoscopic cystectomy on ovarian reserve in endometriotic cysts versus non-endometriotic cysts.",[367,368,369,370,371],"Ovarian Cysts","Endometriosis","Benign Ovarian Cyst","Ovarian Reserve","Cystectomy",[373,371,374,375,376],"Laparoscopy","Endometriotic Ovarian Cysts","Benign Ovarian Cysts","Ovarian Reserve Markers","2026-07-02",{"date":379,"type":38},"2026-07-07",{"date":381,"type":22},"2026-06-30",{"date":383,"type":22},"2027-09",{"name":44,"class":45},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":134,"minAge":55,"maxAge":195,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":393,"briefSummary":394,"conditions":395,"keywords":398,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":46},"100639084","selective-extended-venous-stripping-versus-standard-microsurgical-varicocelectomy-for-varicocele-related-male-infertility-100639084","NCT07605351","Selective Extended Venous Stripping Versus Standard Microsurgical Varicocelectomy for Varicocele-Related Male Infertility","Selective Extended Microsurgical Venous Stripping Versus Standard Microsurgical Subinguinal Varicocelectomy in Infertile Men With Abnormal Semen Parameters: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Male patients aged 18 to 50 years.\n* Couple infertility for at least 12 months.\n* Clinically palpable grade I to III varicocele confirmed by physical examination.\n* Abnormal semen parameters documented on at least two semen analyses performed 2 to 4 weeks apart according to World Health Organization laboratory standards.\n* Female partner evaluation completed or planned, with no untreated severe female factor that would make natural conception impossible.\n* Willingness to comply with postoperative follow-up at 3, 6, and 12 months.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Azoospermia or cryptozoospermia, defined as absence of sperm in the native ejaculate on at least two baseline semen analyses, including cases in which sperm are detected only after centrifugation.\n* Known clinically significant chromosomal or genetic abnormality that independently explains severe male infertility, when identified before enrollment.\n* Previous varicocelectomy of the index side.\n* Previous inguinal, scrotal, or retroperitoneal surgery that may alter spermatic cord anatomy.\n* Subclinical varicocele only.\n* Isolated scrotal pain with normal semen parameters.\n* Hypogonadotropic hypogonadism requiring hormonal induction therapy.\n* Testosterone therapy within the previous 6 months.\n* Use of anti-estrogens, gonadotropins, or aromatase inhibitors within the previous 3 months.\n* Active genitourinary infection.\n* Testicular tumor or history of testicular cancer.\n* Severe systemic disease contraindicating surgery or anesthesia.\n* Inability to provide informed consent.\n* Inability or unwillingness to complete follow-up.",{"count":340,"type":22},[84],"Varicocele is a common correctable cause of male infertility and may be associated with abnormal semen parameters, impaired testicular function, and scrotal discomfort. Microsurgical subinguinal varicocelectomy is a commonly used surgical approach because it allows careful preservation of the testicular artery, lymphatic channels, vas deferens, and vasal vessels under magnification. However, persistent or recurrent varicocele may still occur after surgery, possibly because of missed or persistent venous channels.\n\nThis randomized controlled trial will compare two surgical techniques in infertile men with clinically palpable varicocele and abnormal semen parameters. Participants will be randomly assigned to either microsurgical subinguinal varicocelectomy with selective extended venous stripping or standard microsurgical subinguinal varicocelectomy with conventional vein ligation and division.\n\nThe main purpose of the study is to determine whether selective extended venous stripping reduces the rate of clinically and Doppler-confirmed persistent or recurrent varicocele at 12 months after surgery compared with the standard microsurgical technique. The study will also compare semen parameter improvement, pain improvement in participants with baseline pain, pregnancy outcomes, operative time, postoperative complications, and the need for additional treatment during 12 months of follow-up.",[396,397],"Varicocele","Male Infertility",[396,397,399,400,401,402,403,404,405,406],"Microsurgical Varicocelectomy","Subinguinal Varicocelectomy","Venous Stripping","Semen Analysis","Scrotal Doppler Ultrasound","Varicocele Recurrence","Abnormal Semen Parameters","Pregnancy Outcome","2026-05-18",{"date":409,"type":38},"2026-05-22",{"date":411,"type":22},"2026-06-15",{"date":413,"type":22},"2028-06-15",{"name":44,"class":45},{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":54,"minAge":221,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":23,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":4},"100639139","peng-vs-femoral-nerve-block-for-pain-control-in-hip-surgery-100639139","NCT07597551","PENG vs. Femoral Nerve Block for Pain Control in Hip Surgery","Comparative Study Between Continous Ultrasound Guided Pericapsular Nerve Group (PENG) Block Versus Femoral Nerve Block For Perioperative Pain Control In Hip Surgeries","Inclusion Criteria:\n\n* Aged 40 years or older.\n\n  * Presenting for hip surgeries\n  * No contraindications to regional anesthesia.\n  * Time of surgery up to 3 hours\n  * ASA I-III\n  * Able to provide written informed consent.\n  * Able to reliably report pain and other symptoms to the research team.\n  * Undergoing elective or emergency hip surgeries.\n\nExclusion Criteria:\n\n* Inability to provide first-person consent due to cognitive impairment.\n\n  * Presence of a language barrier that would preclude reliable reporting of symptoms or understanding study procedures.\n  * More than ASA III. 4\n  * Previous neurological deficit in the lower limbs.\n  * Local infection at block area.\n  * Lengthy surgeries more than 3 hours.",{"count":136,"type":22},[84],"The aim of this study is to compare the efficacy of the ultrasound- guided pericapsular nerve group (PENG) block versus the femoral nerve block (FNB) for postoperative pain control in patients undergoing hip surgeries, specifically evaluating pain scores and quadriceps strength.",[426],"Pain, Postoperative","2026-05-16",{"date":429,"type":38},"2026-05-19",{"date":431,"type":22},"2026-05-15",{"date":433,"type":22},"2027-05-15",{"name":44,"class":45},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":195,"enrollmentInfo":442,"targetDuration":4,"studyType":23,"phases":443,"briefSummary":444,"conditions":445,"keywords":450,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":457,"completionDateStruct":458,"leadSponsor":460,"locationsCount":46},"100639970","effects-of-extracorporeal-shockwave-therapy-versus-pulsed-electromagnetic-field-therapy-in-females-with-sexual-dysfunction-100639970","NCT07584174","Effects of Extracorporeal Shockwave Therapy Versus Pulsed Electromagnetic Field Therapy in Females With Sexual Dysfunction.","Effects of Extracorporeal Shockwave Therapy Versus Pulsed Electromagnetic Field Therapy in Females With Sexual Dysfunction: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female participants aged 20-50 years diagnosed with female sexual dysfunction (FSFI score \\\u003C26.55), reporting symptoms of reduced sexual desire, arousal dysfunction, orgasmic dysfunction, or dyspareunia.\n2. Premenopausal women in a stable sexual relationship for at least 6 months and sexually active during the previous month.\n3. Symptoms persisting for at least 3 months before enrollment.\n4. Ability to understand study procedures and provide written informed consent.\n5. Willingness to refrain from initiating any additional treatment for sexual dysfunction during the study period\n\nExclusion Criteria:\n\n1. Pregnancy or planned pregnancy during the study period.\n2. Pelvic surgery within the previous 6 months.\n3. Active pelvic inflammatory disease, genital infection, or unexplained vaginal bleeding.\n4. Neurological disorders affecting pelvic floor or sexual function.\n5. Severe pelvic organ prolapse, severe urinary incontinence, or significant pelvic anatomical abnormalities.\n6. Current hormonal therapy or use of medications known to affect sexual function, including antidepressants or antipsychotics.\n7. Severe psychiatric disorders or cognitive impairment limiting participation.\n8. Menopause or perimenopausal status.\n9. Uncontrolled systemic diseases such as diabetes mellitus, hypertension, cardiovascular disease, or thyroid disorders.\n10. Presence of malignancy, pelvic radiation history, or severe chronic pelvic pain disorders.\n11. Contraindications to ESWT or PEMF including cardiac pacemakers or implanted electronic devices, coagulation disorders, anticoagulant therapy, epilepsy, or metal implants in the pelvic region.\n12. Current participation in another clinical trial or receipt of physiotherapy for sexual dysfunction within the previous 3 months.",{"count":57,"type":22},[84],"This is a prospective, three-arm, parallel-group, assessor-blinded randomized controlled trial designed to compare the effectiveness of extracorporeal shockwave therapy (ESWT) combined with pelvic floor muscle training (PFMT), pulsed electromagnetic field stimulation (PEMF) combined with PFMT, and PFMT alone in Females with sexual dysfunction. Participants will be randomly allocated in a 1:1:1 ratio, and the study duration is 16 weeks, including an 8-week intervention period and an 8-week follow-up period.",[446,447,448,449],"Female Sexual Dysfunction (FSD)","Pelvic Floor Muscle Training","Shock Wave","Pulsed Electromagnetic Therapy",[451,452,453,454],"extracorporeal shock wave therapy","pulsed electromagnetic filed therapy","pelvic floor muscles training","females sexual dysfunction","2026-05-14",{"date":407,"type":38},{"date":455,"type":38},{"date":459,"type":22},"2027-01-15",{"name":44,"class":45},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":469,"enrollmentInfo":470,"targetDuration":4,"studyType":23,"phases":471,"briefSummary":472,"conditions":473,"keywords":477,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":485,"leadSponsor":487,"locationsCount":46},"100637467","telerehabilitation-vs-supervised-physiotherapy-for-medial-epicondylitis-100637467","NCT07582510","Telerehabilitation vs Supervised Physiotherapy for Medial Epicondylitis","Effectiveness of Telerehabilitation Versus Supervised Physiotherapy on Pain, Function, Strength, and Musculoskeletal Ultrasound Parameters in Patients With Medial Epicondylitis: A Randomized Controlled Trial","TELE-ME","Inclusion Criteria:\n\n* Age 18 to 60 years\n* Clinical diagnosis of medial epicondylitis\n* Symptoms duration ≥6 weeks\n* Pain with resisted wrist flexion\n* Local tenderness at medial epicondyle\n\nExclusion Criteria:\n\n* Previous elbow surgery\n* Corticosteroid injection within the past 3 months\n* Cervical radiculopathy\n* Systemic inflammatory disease\n* Bilateral symptoms","60 Years",{"count":363,"type":22},[84],"This randomized controlled trial aims to compare the effectiveness of telerehabilitation and supervised physiotherapy in patients with medial epicondylitis. The primary outcome is improvement in pain and function using the Patient-Rated Elbow Evaluation (PREE). Secondary outcomes include pain intensity, grip strength, musculoskeletal ultrasound findings, adherence, and upper limb disability measured by Quick DASH.",[474,475,476],"Medial Epicondylitis","Telerehabilitation","Physiotherapy",[478,479,480,481,482],"medial epicondylitis","telerehabilitation","grip strength","Patient-Rated Elbow Evaluation","Quick DASH",{"date":407,"type":38},{"date":455,"type":38},{"date":486,"type":22},"2026-12-15",{"name":44,"class":45},{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":134,"minAge":195,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":23,"phases":496,"briefSummary":497,"conditions":498,"keywords":500,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":4},"100638203","comparative-outcomes-of-rezm-versus-echolaser-for-treatment-of-benign-prostatic-hyperplasia-with-enlarged-median-lobe-100638203","NCT07578428","Comparative Outcomes of Rezūm Versus EchoLaser for Treatment of Benign Prostatic Hyperplasia With Enlarged Median Lobe.","Comparative Outcomes of Rezūm (Water Vapor Therapy) Versus EchoLaser (Transperineal Laser Ablation) for Treatment of Benign Prostatic Hyperplasia With Enlarged Median Lobe. A Prospective Randomized Comparative Study.","Inclusion Criteria:\n\nInclusion Criteria:\n\nMale patients aged 50 years or older.\n\nDiagnosis of symptomatic BPH with moderate-to-severe lower urinary tract symptoms, defined as an IPSS ≥ 12.\n\nTotal prostate volume between 30 mL and 80 mL, confirmed via Transrectal Ultrasound (TRUS) or mpMRI.\n\nPresence of an enlarged, obstructing intravesical median lobe visualized via imaging or baseline cystoscopy.\n\nPeak urinary flow rate (Qmax) between 5 and 15 mL\u002Fs with a minimum voided volume of ≥ 125 mL.\n\nExclusion Criteria:\n\nConfirmed or suspected prostate cancer (e.g., PSA \\> 4.0 ng\u002FmL without a subsequent negative prostate biopsy or MRI).\n\nHistory of prior surgical interventions for BPH (e.g., TURP, HOLEP, or other MISTs).\n\nPresence of urethral strictures, bladder neck contracture, or established neurogenic bladder dysfunction.\n\nActive urinary tract infection (UTI) or an episode of acute urinary retention requiring an indwelling catheter at the time of screening.\n\nPrevious pelvic radiation therapy or severe pelvic trauma.\n\nInability to safely pause anticoagulant\u002Fantiplatelet therapy per standard hospital perioperative protocols, if applicable.",{"count":223,"type":22},[84],"This study evaluates and compares two minimally invasive surgical therapies for treating men with benign prostatic hyperplasia (BPH) who specifically have an enlarged median lobe. The two treatments being compared are Rezūm (water vapor thermal therapy) and EchoLaser (transperineal laser ablation). Participants will be randomized into two equal groups to receive either the Rezūm treatment or the EchoLaser treatment. The primary goal of the study is to evaluate the change in urinary symptoms over a 6-month period using the International Prostate Symptom Score (IPSS). The study will also assess how well each treatment improves urine flow, reduces the size of the prostate, preserves sexual function, and minimizes complications.",[499],"Benign Prostatic Hyperplasia",[501,502],"Rezūm","EchoLaser","2026-05-05",{"date":505,"type":38},"2026-05-11",{"date":507,"type":22},"2026-05-01",{"date":509,"type":22},"2027-05-01",{"name":44,"class":45},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":134,"minAge":519,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":522,"briefSummary":523,"conditions":524,"keywords":527,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":46},"100633437","concomitant-trans-perineal-prostate-biopsy-and-ablation-bioblation-for-prostate-cancer-100633437","NCT07526675","Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer","Validation of Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Symptomatic (LUTS) Selected Most Probably Low and Intermediate Risk PCa Patients","Bioblation","Inclusion Criteria:\n\n* Patients with severe Lower Urinary Tract Symptoms (LUTS) meeting the following parameters:\n\n  1. IPSS score \\> 20\n  2. Uroflowmetry flow rate \\\u003C 10 ml\u002Fsec\n  3. Post-void residual \\> 150 cc\n* Patients most probably having low to favorable intermediate-risk prostate cancer, defined as:\n\n  1. PSA level between 4 and 20 ng\u002Fml\n  2. MP-MRI showing 3 or fewer focal lesions\n  3. MP-MRI focal lesions measuring \\\u003C 1.5 cm\n* International or visiting patients requiring early return to their home country due to professional or personal commitments, provided they can undergo short-term management and follow-up coordination\n\nExclusion Criteria:\n\n* Patient PSA level \\> 20 ng\u002Fml\n* More than 3 focal lesions on MP-MRI\n* Metastatic prostate cancer\n* History of lower urinary tract surgery (e.g., TURP, Laser, urinary diversions, artificial urinary sphincter)\n* History of pelvic radiation therapy or radical pelvic surgery","18 Months",{"count":521,"type":22},30,[84],"This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed \"Bioblation\") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.",[525,526,499],"Prostate Cancer","Lower Urinary Tract Symptoms (LUTS)",[525,528,517,529,141,499],"Transperineal Laser Ablation","Focal Therapy","2026-04-09",{"date":532,"type":38},"2026-04-13",{"date":534,"type":22},"2026-04-10",{"date":536,"type":22},"2026-04-28",{"name":44,"class":45},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":196,"enrollmentInfo":545,"targetDuration":4,"studyType":23,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":46},"100629850","determination-of-the-optimal-inspiratory-pressure-to-decrease-incidence-of-gastric-insufflation-with-adequate-ventilation-during-facemask-ventilation-in-morbidly-obese-patients-100629850","NCT07480031","Determination of the Optimal Inspiratory Pressure to Decrease Incidence of Gastric Insufflation With Adequate Ventilation During Facemask Ventilation in Morbidly Obese Patients","Ultrasound-Guided Optimization of Inspiratory Pressure During Facemask Ventilation in Morbidly Obese Patients to Prevent Gastric Insufflation: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Adult patients (18-65 years old) scheduled for elective surgery under general anesthesia requiring facemask ventilation.\n\n  * Morbid obesity (BMI ≥40 kg\u002Fm²).\n  * American Society of Anesthesiologists (ASA) physical status II-III.\n  * Normal upper gastrointestinal anatomy (no history of gastric surgery, esophageal strictures, or hiatus hernia).\n  * Fasted for at least 6 hours for solids and 2 hours for fluids (standard preoperative fasting guidelines).\n\nExclusion Criteria:\n\n* • Emergency surgery (due to inability to ensure proper fasting or preoperative assessment).\n\n  * Known or suspected difficult airway (Mallampati class IV, limited neck mobility, or history of difficult intubation).\n  * Gastroesophageal reflux disease (GERD) or high aspiration risk (e.g., pregnancy, symptomatic hiatal hernia).\n  * Contraindications to facemask ventilation (facial trauma, beard\u002Fmask seal interference).\n  * Severe cardiopulmonary disease (e.g., severe COPD, pulmonary hypertension, or unstable angina).\n  * Neuromuscular disorders affecting respiratory function.\n  * Refusal to participate or inability to provide informed consent.",{"count":546,"type":22},144,[84],"The goal of this randomized clinical trial is to optimize the inspiratory pressure during facemask ventilation (FMV) in morbidly obese patients (BMI ≥40 kg\u002Fm²), to ensure adequate ventilation while minimizing the risk of gastric insufflation by real-time ultrasound guidance",[550],"Gastric Insufflation","2026-03-14",{"date":553,"type":38},"2026-03-18",{"date":555,"type":22},"2026-04-01",{"date":557,"type":22},"2027-04-15",{"name":44,"class":45},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":54,"minAge":566,"maxAge":567,"enrollmentInfo":568,"targetDuration":4,"studyType":23,"phases":570,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":46},"100627011","phase-2-effect-of-dexmedetomidine-dosage-on-postoperative-delirium-in-geriatric-orthopedic-surgery-100627011","NCT07443085","Effect of Dexmedetomidine Dosage on Postoperative Delirium in Geriatric Orthopedic Surgery","Dose-Effect Relationship of Dexmedetomidine on Delirium and Cognitive Function After Lower Limb Orthopedic Surgeries for Elderly Patients","Inclusion Criteria:\n\n* Elderly surgical patients.\n* ASA physical status grade II-III.\n* Planned major lower limb orthopedic surgery.\n\nExclusion Criteria:\n\n* pre-existing dementia or drug allergies","55 Years","70 Years",{"count":569,"type":22},75,[25],"This study evaluates the dose-response relationship of Dexmedetomidine (DEX) in reducing the incidence and severity of postoperative delirium (POD) and postoperative cognitive dysfunction (POCD) in elderly patients. The study compares different doses of DEX against a fentanyl control group in patients undergoing major lower limb orthopedic surgery under general anesthesia to determine the optimal dosage for cognitive protection.",[573],"Delirium - Postoperative","2026-02-27",{"date":576,"type":38},"2026-03-02",{"date":578,"type":38},"2026-02-26",{"date":580,"type":22},"2027-10",{"name":44,"class":45},{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":196,"enrollmentInfo":588,"targetDuration":4,"studyType":23,"phases":589,"briefSummary":590,"conditions":591,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":46},"100621093","ultrasound-guided-external-oblique-intercostal-plane-block-versus-subcostal-transversus-abdominis-plane-block-for-perioperative-analgesia-in-laparoscopic-sleeve-gastrectomy-100621093","NCT07366138","Ultrasound-Guided External Oblique Intercostal Plane Block Versus Subcostal Transversus Abdominis Plane Block For Perioperative Analgesia in Laparoscopic Sleeve Gastrectomy","Inclusion Criteria:\n\n* Age from 18 to 65 years.\n* Both genders.\n* American Society of Anesthesiologists (ASA) class I or II\n* Body mass index (BMI) between 30-50 kg\u002Fm².\n* Scheduled for elective laparoscopic sleeve gastrectomy under general anesthesia.\n* Written informed consent from patients or surrogate decision makers.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Allergy to local anesthetics.\n* Coagulation disorders or anticoagulant therapy.\n* Local infection or scar at the injection site.\n* Severe hepatic or renal dysfunction.\n* Chronic opioid use or psychiatric illness interfering with pain assessment.\n* Conversion to open surgery or intraoperative complications requiring re-exploration.",{"count":294,"type":22},[84],"This study aims to compare the analgesic efficacy, duration of analgesia, and overall opioid consumption between the external oblique intercostal plane (EOIP) block and subcostal transversus abdominis plane (TAP) block in patients undergoing laparoscopic sleeve gastrectomy.",[592,593,594,595,596],"Ultrasound","External Oblique Intercostal Plane Block","Subcostal Transversus Abdominis Plane Block","Perioperative Analgesia","Laparoscopic Sleeve Gastrectomy","2026-01-17",{"date":599,"type":38},"2026-01-26",{"date":601,"type":38},"2025-11-01",{"date":603,"type":22},"2026-11-01",{"name":44,"class":45},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":23,"phases":614,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":626,"leadSponsor":627,"locationsCount":46},"100619378","virtual-reality-versus-intravenous-dexmedetomidine-on-maternal-anxiety-stress-hemodynamics-and-neonatal-outcomes-during-cesarean-section-100619378","NCT07343843","Virtual Reality Versus Intravenous Dexmedetomidine on Maternal Anxiety, Stress, Hemodynamics, and Neonatal Outcomes During Cesarean Section","Effect of Virtual Reality Versus Intravenous Dexmedetomidine on Maternal Anxiety, Stress, Hemodynamics, and Neonatal Outcomes During Cesarean Section","Inclusion Criteria:\n\n* Age over 18 years old.\n* American Society of Anesthesiologists (ASA) physical status II.\n* Scheduled for elective cesarean section (CS) delivery under Central Neuraxial Blockade.\n* Provide informed consent and agree to participate in the study.\n\nExclusion Criteria:\n\n* Patient's refusal\n* Patient known have contraindications for Regional Anesthesia as infection at the site of injection, severe coagulopathy or allergy to local anesthetics.\n* Patient with psychiatric disorders.\n* Sensory impairment (blindness, deafness).\n* Any technical problem preventing proper fitting of the glasses to the patient face.\n* Patients with cognitive impairment, epilepsy or with claustrophobia\n* Patients with suspected eye infection\n* Signs of active labor.\n* Pregnancy related-diseases or antepartum hemorrhage.\n* Presence of Fetal distress.",{"count":613,"type":22},52,[84],"This study aims to compare the efficacy of intravenous dexmedetomidine infusion versus virtual reality (VR) in reducing maternal anxiety, stress, and hemodynamic instability during cesarean section and their effects on neonatal outcome as respiration and heart rate.",[617,347,618,619,620,621,622],"Virtual Reality","Maternal Anxiety","Stress","Hemodynamics","Neonatal Outcomes","Cesarean Section",{"date":624,"type":38},"2026-01-21",{"date":597,"type":38},{"date":95,"type":22},{"name":44,"class":45},{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":195,"enrollmentInfo":635,"targetDuration":4,"studyType":199,"phases":4,"briefSummary":637,"conditions":638,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":46},"100619608","role-of-circulating-micrornas-in-differentiating-psychological-disorders-among-women-with-chronic-toxoplasmosis-100619608","NCT07346833","Role of Circulating MicroRNAs in Differentiating Psychological Disorders Among Women With Chronic Toxoplasmosis","Deciphering The Role of Circulating MicroRNAs To Differentiate Psychological Disorders Among Women With Chronic Toxoplasmosis","Inclusion Criteria:\n\n* Confirmed psychiatric diagnosis of Schizophrenia (SCZ), Major Depressive Disorder (MDD), or Bipolar Disorder (BD) according to DSM-5 criteria.\n* Seronegative for T. gondii IgM (to ensure infection is not in the acute phase).\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Psychiatric disorders other than Schizophrenia, MDD, and Bipolar Disorder.\n\nSeropositive for T. gondii IgM (indicating acute infection).\n\nRefusal to participate.",{"count":636,"type":22},55,"Chronic Toxoplasma gondii (T. gondii) infection is a widespread condition that can negatively affect brain function and is considered a risk factor for various psychiatric conditions, including depression and schizophrenia. This prospective observational study aims to investigate the expression levels of specific circulating microRNAs (miRNAs) in women diagnosed with schizophrenia, major depressive disorder, or bipolar disorder who also have chronic toxoplasmosis. By comparing these levels to patients without the infection, the study seeks to determine if these miRNAs can serve as biological markers to help differentiate between specific psychological disorders and identify the impact of chronic toxoplasmosis on mental health.",[639],"Toxoplasmosis","2026-01-08",{"date":642,"type":38},"2026-01-16",{"date":644,"type":38},"2025-11-20",{"date":646,"type":22},"2026-04",{"name":44,"class":45},""]